Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Long-Term Debt Repayments (2024)

Xilio Therapeutics' Long-Term Debt Repayments history spans 1 years, with the latest figure at $3.3 million for Q1 2024.

  • For Q1 2024, Long-Term Debt Repayments changed N/A year-over-year to $3.3 million; the TTM value through Dec 2024 reached $3.3 million, changed N/A, while the annual FY2024 figure was $3.3 million, 50.01% down from the prior year.
  • Long-Term Debt Repayments for Q1 2024 was $3.3 million at Xilio Therapeutics.
  • Across five years, Long-Term Debt Repayments topped out at $3.3 million in Q1 2024 and bottomed at $3.3 million in Q1 2024.